Back to search results

A Study of LY4088044 in Healthy Participants

This study is looking at a drug called LY4088044 in healthy volunteers. The main goal is to see how well your body tolerates LY4088044 and what side effects might occur. You would receive LY4088044 or a placebo (an inactive substance) either as an injection under the skin (subcutaneously) or into a vein (intravenously). Researchers will also take blood samples to understand how much of the drug enters your bloodstream and how quickly your body removes it. This study is for healthy individuals aged 18 to 65 with a BMI between 18.5 and 30. The study will measure serious side effects up to about Day 190.

Study design
This is an interventional study planning to enroll 104 healthy participants. It involves giving participants either LY4088044 or a placebo.
What's involved
The study will last up to approximately 92 weeks, not including the initial screening. It involves receiving the study drug and having blood tests.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for serious adverse events (side effects) up to approximately Day 190 after starting the study drug.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07090785

A Study of LY4088044 in Healthy Participants

Recruiting
PHASE1Ages 18–65InterventionalBasic science
Eli Lilly and Company
~104 participants
Updated 2026-08-07 on ClinicalTrials.gov
What's tested:LY4088044Placebo

At a glance

Recruiting sites
4 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Measured over Baseline up to Approximately Day 190

Conditions

Healthy

Explore related trials

Healthy

Where it's being run

6 sites across 6 states
California1
Kansas1
Texas1
Utah1
New Zealand1
Singapore1

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
[email protected]
1-317-615-4559
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring
Have a body mass index (BMI) within the range 18.5 to 30 kilogram per square meter (kg/m²)

Exclusion

Are individuals assigned female at birth (AFAB) who are pregnant and/or lactating
Regularly use known drugs of abuse or show positive findings on urinary drug screening that are not consistent with their medication history
Participants with hemoglobin outside of the local laboratory normal range for age and gender, or evidence of iron deficiency, or hemoglobinopathy
Participants with estimated glomerular filtration rate (GFR) less than 90 milliliter per minute per 1.73 square meter (mL/min/1.73 m²)
Have a 12-lead electrocardiogram (ECG) abnormality
Smoke more than 10 cigarettes per day or the equivalent including electronic cigarettes AND are unable to abide by investigative site smoking restrictions
Have an average weekly alcohol intake that exceeds 21 units per week (males less than or equal to 65 years old) and 14 units per week (females and males over 65-year-old, if applicable) and are unwilling to abide by the restrictions

What this trial measures

  • Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationBaseline up to Approximately Day 190

    A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module